Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial

托珠单抗 医学 类风湿性关节炎 生物仿制药 临床终点 内科学 甲氨蝶呤 不利影响 痹症科 随机对照试验
作者
Xiaomei Leng,Piotr Leszczyński,Sławomir Jeka,Shengyun Liu,Huaxiang Liu,Małgorzata Miakisz,Jieruo Gu,Lali Kilasonia,Mykola Stanislavchuk,Xiaolei Yang,Yinbo Zhou,Qingfeng Dong,Mourad Farouk Rezk,Marian Mitroiu,Janet Addison,Xiaofeng Zeng
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:6 (1): e40-e50 被引量:24
标识
DOI:10.1016/s2665-9913(23)00237-0
摘要

Background Biosimilars provide an opportunity to address unmet medical need by expanding access to biological treatments. This study aimed to show equivalent efficacy, and comparable safety, immunogenicity, and pharmacokinetic profiles of a proposed tocilizumab biosimilar BAT1806/BIIB800, to reference tocilizumab, in participants with rheumatoid arthritis with an inadequate response to methotrexate. Methods This phase 3, multicentre, randomised, double-blind, active-controlled, equivalence study comprised a 24-week initial treatment period (results reported here) and a 24-week secondary treatment period. Participants were recruited at 54 centres across five countries (China, Ukraine, Poland, Georgia, and Bulgaria). Patients with active rheumatoid arthritis with an inadequate response to methotrexate were randomly assigned (1:1:2) to receive reference tocilizumab up to week 48, or reference tocilizumab up to week 24 followed by BAT1806/BIIB800 up to week 48 (the two reference tocilizumab groups were analysed as a single group in this analysis), or BAT1806/BIIB800 up to week 48 (the BAT1806/BIIB800 group), administered by intravenous infusion once every 4 weeks at a starting dose of 8 mg/kg. The primary endpoint was the proportion of participants who had a 20% improvement in American College of Rheumatology criteria (ACR20) at week 12 (for the European Medicines Agency [EMA]) or week 24 (for the US Food and Drug Administration [FDA] and China National Medical Products Administration [NMPA]) using prespecified equivalence margins (95% CI –14·5 to +14·5 [EMA], 90% CI –12·0 to +15·0 [FDA], and 95% CI –13·6 to +13·6 [NMPA]). The International Council for Harmonisation E9(R1) estimand framework, with strategies for addressing intercurrent events, was implemented for the efficacy evaluations with expected differences as per the predefined equivalence margins. This trial is registered at ClinicalTrials.gov (NCT03830203) and EudraCT (2018-002202-31), and is closed to new participants. Findings Between Dec 19, 2018, and Jan 5, 2021, we randomly assigned 621 participants: 309 to the reference tocilizumab group and 312 to the BAT1806/BIIB800 group. The mean age was 50·5 years (SD 12·0), 534 (86%) were women, 87 (14%) were men, and 368 (59%) were White. For the primary estimands, estimated ACR20 response rates were 64·8% in the reference tocilizumab group and 69·0% in the BAT1806/BIIB800 group (treatment difference 4·1% [95% CI –3·6 to 11·9]) at week 12, and 67·9% in the reference tocilizumab group and 69·9% in the BAT1806/BIIB800 group (treatment difference 1·9% [90% CI –4·0 to 7·9; 95% CI –5·2 to 9·1]) at week 24. All confidence intervals were contained within the predefined equivalence margins. Comparable pharmacokinetic and immunogenicity profiles were observed for the reference tocilizumab and BAT1806/BIIB800 groups. Adverse events were reported by 201 (65%) participants in the reference tocilizumab group and 206 (66%) in the BAT1806/BIIB800 group; 196 (63%) participants in the reference tocilizumab group and 201 (64%) participants in the BAT1806/BIIB800 group reported a treatment-emergent adverse event. Five participants had a fatal event (reference tocilizumab n=1; BAT1806/BIIB800 n=4). Interpretation BAT1806/BIIB800 showed equivalent efficacy, and comparable safety, immunogenicity, and pharmacokinetic profiles as reference tocilizumab. Funding Bio-Thera Solutions and Biogen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
开朗醉波完成签到,获得积分10
1秒前
阳阳完成签到 ,获得积分10
1秒前
传奇3的应助被大胆的灰狼采纳,获得10
2秒前
xyf完成签到 ,获得积分10
4秒前
chen完成签到 ,获得积分10
6秒前
手帕很忙完成签到,获得积分10
7秒前
itzbot1245完成签到,获得积分10
8秒前
优美奇异果完成签到 ,获得积分10
8秒前
常青树完成签到,获得积分10
8秒前
ReginaLee完成签到 ,获得积分10
8秒前
威武的念波完成签到,获得积分10
9秒前
阳光的Kelly完成签到 ,获得积分10
10秒前
Zoeyren完成签到,获得积分10
11秒前
小芒果完成签到,获得积分10
12秒前
会赢完成签到 ,获得积分10
13秒前
Yanzhi完成签到,获得积分10
14秒前
16秒前
17秒前
玖月完成签到 ,获得积分0
17秒前
Yexin完成签到,获得积分10
19秒前
19秒前
麒麟发布了新的文献求助10
21秒前
LSQ47完成签到,获得积分10
21秒前
qinyaopanda发布了新的文献求助10
24秒前
风雨晴鸿完成签到 ,获得积分10
25秒前
科研通AI6.2的应助被son采纳,获得10
26秒前
Island完成签到 ,获得积分10
26秒前
机智的访云完成签到,获得积分10
26秒前
众行绘研完成签到 ,获得积分10
26秒前
拂晓完成签到,获得积分10
28秒前
义气绍辉完成签到,获得积分10
28秒前
高兴薯片完成签到 ,获得积分10
30秒前
青云完成签到,获得积分10
30秒前
pmsl完成签到,获得积分10
32秒前
清爽的人龙完成签到 ,获得积分10
33秒前
糖诗完成签到 ,获得积分10
33秒前
饿哭了塞完成签到 ,获得积分10
34秒前
无心的千雁完成签到,获得积分10
34秒前
灵巧小夏完成签到,获得积分10
34秒前
汪欣怡完成签到 ,获得积分10
35秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173350
求助须知:如何正确求助?哪些是违规求助? 9565632
关于积分的说明 21780706
捐赠科研通 7767517
什么是DOI,文献DOI怎么找? 3431557
关于科研通互助平台的介绍 2555846
邀请新用户注册赠送积分活动 2476749